Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva Pharmaceuticals (TEVA) over its anti-depressant drug Auvelity.

Barclays analyst Balaji Prasad maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $242.00. The company’s ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Shares in the brain drug developer ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

The Eagles have landed and claimed another Super Bowl victory. Philadelphia defeated the Kansas City Chiefs 40-22 Sunday, to ...

This year’s inductees into the National Baseball Hall of Fame have made their cap logo choices for their plaques. Or, more ...

After hours: 7:25:23 p.m. EST ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.